It's one of the year's most-talked-about cancer stories, but it's not about the disease itself.
Instead, it's about the science behind it.
In the latest issue of CURE, the journal for the American Cancer Society, researchers report on the "unprecedented" progress being made in the treatment of bladder cancer.
The FDA has approved two new treatments: Anktiva, which uses the BCG vaccine to treat non-muscle-invasive bladder cancer, and Opdivo, which uses the antibodynivolumab to treat unresectable or metastatic urothelial carcinoma.
The bladder cancer treatment "hasrevolutionized the way we're looking at bladder cancer," one expert tells CURE, while another says that chemotherapy has long been the standard of care for this type of cancer.
In a clinical trial, patients who received Opdivo plus cisplatin and gemcitabine lived longer than those who received the chemotherapy drugs cisplatin and gemcitabine, reports the New York Times, which notes that this is the first time an FDA-approved treatment has been shown to extend the lives of people with this type of cancer.
(Click to read about another "groundbreaking" cancer study
Read the Entire Article
A customized collection of news from foundations from around the Web.
Entrepreneurs Unlocked, a Bolton-based social enterprise, has received National Lottery funding to expand its mentoring program to 200 prison inmates in the Northwest.